Lytix Biopharma As
Clinical trials sponsored by Lytix Biopharma As, explained in plain language.
-
Experimental combo therapy targets hard-to-treat sarcoma
Disease control CompletedThis study tested a two-step treatment for people with advanced soft tissue sarcoma that had stopped responding to standard therapy. First, a drug called LTX-315 was injected into a tumor to attract immune cells. Then, that tumor was removed, and the immune cells were grown in a …
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo shot aims to reignite immune attack on tough melanoma
Disease control CompletedThis phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slo…
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC